Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen (PADD-ON)

This study is ongoing, but not recruiting participants.
Roche Pharma AG
Information provided by (Responsible Party):
Peter R. Galle, Johannes Gutenberg University Mainz Identifier:
First received: January 31, 2012
Last updated: March 7, 2017
Last verified: March 2017

A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated interferon alfa-2a(Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B

The primary objective of the trial is to investigate whether the add-on of pegylated interferon alfa-2a to a continued treatment with nucleos(t)ide analogues increases the percentage of patients who have significant decrease (≥ 1log10) of HBs antigen after 48 weeks.

170 Patients with chronic hepatitis B, HBe antigen negative, already being treated with an oral antiviral regimen and having a nondetectable viral load for at least 12 months are included.

Condition Intervention Phase
Chronic Hepatitis B
Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys®)180 μg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B

Resource links provided by NLM:

Further study details as provided by Johannes Gutenberg University Mainz:

Primary Outcome Measures:
  • Difference in percentage of patients between treatment and comparator arm reaching a ≥ 1log10 decline of quantitative HBsAg after 48 weeks [ Time Frame: 48 weeks ]
    Difference in percentage of patients between treatment and comparator arm reaching a ≥ 1log10 decline of quantitative HBsAg after 48 weeks

Secondary Outcome Measures:
  • Decline of quantitative HBs antigen at week 12 and 24 [ Time Frame: 12 and 24 weeks ]
    Decline of quantitative HBs antigen at week 12 and 24

Estimated Enrollment: 170
Study Start Date: August 2012
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment group
pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
Other Name: Pegasys®
No Intervention: Control group
ongoing nucleos(t)ide based treatment alone


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic hepatitis B, HBe antigen negative
  • treatment with a stable oral antiviral treatment (not containing telbivudine) and a fully suppressed viral load for at least 12 months (below limit of detection in conventional HBV-PCR assays, i.e. <116 IU / ml).
  • 18-70 ys
  • willingness and ability to give informed consent and to follow study procedures
  • willingness to use adequate contraception

Exclusion Criteria:

  • contraindications against treatment with pegylated interferon, e.g. depression, uncontrolled epilepsy, autoimmune diseases, pregnancy, leukocytopenia or thrombocytopenia at screening, etc.
  • active alcohol or drug abuse
  • preexisting polyneuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01524679

Facharztpraxis Prof. Löhr
Wiesbaden, Hessen, Germany, 65185
Universitätsklinikum Aachen, Medizinische Klinik III
Aachen, Germany, 52074
Leber- und Studienzentrum am Checkpoint
Berlin, Germany, 10969
Charité Campus Virchow Klinikum, Universitätsmedizin Berlin
Berlin, Germany, 13353
Medizinische Klinik und Poliklinik I, Universitätsklinik Bonn
Bonn, Germany, 53105
Medizinisches Versorgungszentrum Dr. Mauss, Schmutz, Dr. Athmann, Dr. Hegener
Düsseldorf, Germany, 40237
Medizinische Klinik I, Klinik der J.W. Goethe Universität
Frankfurt, Germany, 60590
Teuber Consulting & Research KG
Frankfurt, Germany, 60594
Universitätsklinikum Freiburg Innere Medizin II
Freiburg, Germany, 79106
Universitätsklinikum Gießen und Marburg GmbH
Gießen, Germany, 35392
Universitätsklinikum Hamburg-Eppendorf, I. Med. Klinik und Poliklinik
Hamburg, Germany, 20246
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie
Hannover, Germany, 30625
Universitätsklinikum Heidelberg, Medizinische Klinik IV
Heidelberg, Germany, 69120
Universitätsklinikum des Saarlandes
Homburg, Germany, 66421
Universitätsklinik Schleswig-Holstein Campus Kiel Klinik für Allgemeine Innere Medizin
Kiel, Germany, 24105
Klinik für Gastroenterologie und Hepatologie am Abdominalzentrum Universitätsklinikum Köln
Köln, Germany, 50937
Universitätsklinikum Leipzig AöR
Leipzig, Germany, 04103
Universitätsmedizin Mainz, I. Med. Klinik und Poliklinik
Mainz, Germany, 55131
Universitätsklinikum Mannheim
Mannheim, Germany, 68167
Klinikum rechts der Isar der Technischen Universität München
München, Germany, 81675
Universitätsklinikum Regensburg
Regensburg, Germany, 93053
Uniklinik Tübingen Innere Medizin Abt. I
Tübingen, Germany, 72076
Universitätsklinikum Ulm, Zentrum für Innere Medizin
Ulm, Germany, 89081
Klinikum der Universität Würzburg Zentrum für Innere Medizin (ZIM) Medizinische Klinik und Poliklinik II Leber- und Infektionsambulanz
Würzburg, Germany, 97080
Sponsors and Collaborators
Johannes Gutenberg University Mainz
Roche Pharma AG
Principal Investigator: Peter R. Galle, Univ.-Prof. Dr. med. I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz
  More Information

Sprinzl MF, Grambihler A, Kittner JM, Wachtlin D, Ruckes C, et al. (2015) Prospective Randomized Open-label Trial Protocol Investigating the Addition of Pegylated Interferon-alpha to an Ongoing Nucleos(t)ide Treatment Regimen of HBeAg Negative Chronic Hepatitis B Patients (PADD-ON). J Clin Trials 5: 226. doi:10.4172/2167-0870.1000226

Responsible Party: Peter R. Galle, Univ.-Prof. Dr. med., Johannes Gutenberg University Mainz Identifier: NCT01524679     History of Changes
Other Study ID Numbers: ML 27787
Study First Received: January 31, 2012
Last Updated: March 7, 2017

Keywords provided by Johannes Gutenberg University Mainz:
chronic hepatitis B

Additional relevant MeSH terms:
Hepatitis A
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017